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RAP1 is part of shelterin, the protective complex at
telomeres. RAP1 also binds along chromosome
arms, where it is proposed to regulate gene expres-
sion. To investigate the nontelomeric roles of RAP1
in vivo, we generated a RAP1 whole-body knockout
mouse. These mice show early onset of obesity,
which is more severe in females than in males.
Rap1-deficient mice show accumulation of abdom-
inal fat, hepatic steatosis, and high-fasting plasma
levels of insulin, glucose, cholesterol, and alanine
aminotransferase. Gene expression analyses of liver
and visceral white fat from Rap1-deficient mice
before the onset of obesity show deregulation of
metabolic programs, including fatty acid, glucose
metabolism, and PPARa signaling. We identify
Ppara and Pgc1a as key factors affected by
Rap1 deletion in the liver. We show that RAP1
binds to Ppara and Pgc1a loci and modulates
their transcription. These findings reveal a role for
a telomere-binding protein in the regulation of
metabolism.
INTRODUCTION
Mammalian telomeres are composed of tandem repeats of the
TTAGGG sequence bound by a specialized protein complex
known as shelterin, which protects chromosome ends and reg-
ulates telomerase activity (Blasco, 2007; Celli and de Lange,
2005; Chin et al., 1999; d’Adda di Fagagna et al., 2003; de
Lange, 2005; Karlseder et al., 1999; Martı´nez and Blasco,
2010, 2011; Palm and de Lange, 2008; Takai et al., 2003; Tejera
et al., 2010; van Steensel et al., 1998). The shelterin complex is
composed of six core proteins: TRF1, TRF2, TIN2, POT1,
TPP1, and RAP1 (de Lange, 2005). TRF1, TRF2, and POT1
bind directly to telomeric DNA repeats, with TRF1 and TRF2
binding to telomeric double-stranded DNA and POT1 to theC30 singled-stranded G overhang. TIN2 is able to bind TRF1
and TRF2 through independent domains and to recruit the
TPP1-POT1 complex, bridging the different shelterin compo-
nents (Chen et al., 2008; Kim et al., 2004; Ye et al., 2004).
RAP1 binds to telomeric repeats through its interaction with
TRF2 (Celli and de Lange, 2005; Li and de Lange, 2003; Li
et al., 2000) and protects from telomere fragility and recombi-
nation, although it is dispensable for telomere capping (i.e.,
protection from telomere fusions) (Martinez et al., 2010; Sfeir
et al., 2010).
Interestingly, RAP1 is conserved from budding yeast to
humans (Li et al., 2000; Shore and Nasmyth, 1987). In budding
yeast, scRap1 is the major binding activity at telomeres where
it controls telomere length and the establishment of subtelomeric
silencing through recruitment of the Sir proteins (Carmen et al.,
2002; Hecht et al., 1995; Imai et al., 2000; Kyrion et al., 1993;
Marcand et al., 1997; Tanny et al., 1999). Besides its role at telo-
meres, scRap1 also acts as a transcription factor by controlling
the expression of glycolytic enzymes and ribosomal genes,
hence its name Repressor activator protein 1 (Buchman et al.,
1988; Capieaux et al., 1989).
These extratelomeric roles of scRap1 in silencing and in
modulating transcription were recently found to be conserved
in mammals (Martinez et al., 2010). In particular, by using chro-
matin immunoprecipitation sequencing (ChIP-seq), we recently
demonstrated that mouse RAP1 binds in vivo to telomeric
repeats as well as throughout chromosome arms, preferentially
by recognition of the (TTAGGG)2 consensus motif (Martinez
et al., 2010). Nontelomeric RAP1-binding sites are enriched at
subtelomeric regions where RAP1 contributes to repression of
subtelomeric genes (Kyrion et al., 1993; Martinez et al., 2010;
Yang et al., 2009). Interestingly, a significant proportion of the
extratelomeric RAP1-binding sites are associated with genes
deregulated upon Rap1 deletion, suggesting a role for RAP1 in
transcriptional regulation (Martinez et al., 2010). Intriguingly,
gene set enrichment analysis (GSEA) of Rap1 null mouse embry-
onic fibroblasts (MEFs) revealed deregulation of pathways
involved in cell adhesion and metabolism, including the peroxi-
some proliferator-activated receptor (PPAR) pathway (Martinez
et al., 2010).ell Reports 3, 2059–2074, June 27, 2013 ª2013 The Authors 2059
Figure 1. Rap1 Deficiency Leads to Onset of Obesity
(A) Body weight curves of wild-type and Rap1 null males (left panel) and females (right panel) on a standard chow diet (18% calories from fat). Values and error
bars represent the mean and SE, respectively.
(B) Weight increment in Rap1-deficient mice compared to wild-type controls monitored at 10-week intervals throughout the mice lifespan.
(C) Representative images of wild-type and Rap1-deficient females at the indicated ages.
(D) Relative food intake and output values normalized by body weight monitored during a week period in metabolic cages in young (5 weeks old, left panel) and
adult females (35–60 weeks old, right panel).
(E and F) EE and RER in male (E) and female (F) mice at the age of 8–12 weeks.
(legend continued on next page)
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Nutrient metabolism and energy homeostasis are tightly
controlled by numerous regulatory systems involving specific
transcription factors. The PPARs are ligand-activated tran-
scription factors that belong to the superfamily of nuclear hor-
mone receptors and play a key role in nutrient homeostasis
(Kersten et al., 2000). Mounting evidence supports a link
between the PPARs and diabetes, obesity, dyslipidemia, and
inflammation. The PPAR family consists of PPARa, PPARd
(also known as PPARb), and PPARg. Ligand-induced activa-
tion of PPARs controls the expression of genes involved in
energy homeostasis, lipid and lipoprotein metabolism, car-
bohydrate metabolism, and inflammation (Kidani and Ben-
singer, 2012). In particular, PPARa is a key regulator of hepatic
fatty acid metabolism through direct transcriptional upregula-
tion of genes involved in peroxisomal and mitochondrial
b-oxidation pathways, fatty acid uptake, and triglyceride meta-
bolism, especially during fasting (Sanderson et al., 2010).
PPARa also has pleiotropic anti-inflammatory and antiprolifera-
tive effects. Indeed, synthetic PPARa agonists are used to treat
dyslipidemia and to reduce cardiovascular disease and its
complications in patients with metabolic syndrome (Lefebvre
et al., 2006).
Here, we report that RAP1 plays a role in metabolism through
regulation of the PPARa and PGC1a genes. In particular, we
show that binding of RAP1 to Ppara and Pgc1a loci is required
for proper Ppara and Pgc1a transcriptional activation. In the
absence of RAP1, PPARa and PGC1a levels are decreased
leading to deregulation of several of their target genes and
the subsequent deregulation of metabolic pathways involved
in energy homeostasis. These molecular defects result in
the development of obesity in Rap1-deficient mice, which is
aggravated with increasing age. Similar to Ppara- and Pgc1a-
deficient mice (Akiyama et al., 2001; Costet et al., 1998; Kim
et al., 2003; Lee et al., 1995; Leone et al., 2005), fat accumula-
tion is more pronounced in Rap1-deficient females than in
males, and they develop pathologies that are reminiscent
of metabolic syndrome in humans, further supporting that
RAP1 and PPARa are in the same pathway for regulation of
metabolism.
RESULTS
Generation of Whole-Body Rap1-Deficient Mice
To study the nontelomeric roles of RAP1 in the adult organism,
we generated a whole-body constitutive Rap1 knockout mouse,
Rap1/, by crossing Rap1flox/flox mice (Martinez et al., 2010)
with transgenic mice carrying the cre recombinase under the
control of the adenovirus EIIa promoter, which targets expres-
sion of the cre to the early stages of embryonic development,
oocytes, and preimplantation embryos (Experimental Proce-
dures). By using this strategy, the resulting gene alterations are
genetically fixed and passed onto the progeny (Lakso et al.,
1996).(G) Lean/fat ratio, plasma-free fatty acids, ketone bodies, and glucose level in fe
Error bars in (B) and (D)–(G) represent the SD. Statistical significance was determi
significant.
See also Figure S1.
CRap1-Deficient Mice Are Viable but Show an Early Onset
of Obesity
Rap1-deficient mice were born at the expected Mendelian ratios
indicating absence of embryonic lethality. Moreover, Rap1-defi-
cient mice showed a normal median survival compared to wild-
type controls (Figures S1A–S1C). These findings indicate that
RAP1 is dispensable for embryonic development and adult
viability, in accordance with normal telomere capping in the
absence of Rap1 (Martinez et al., 2010; Sfeir et al., 2010).
Interestingly, Rap1-deficient mice showed a significant in-
crease in the rate of body weight gain compared to wild-type
controls under the same feeding conditions (standard mouse
chow diet ad libitum; Experimental Procedures) (Figures 1A
and 1B). At 10–20 weeks of age, Rap1-deficient males showed
a 10%–15% increase in body weight compared to wild-type
males, and this increased body weight was maintained
throughout their lifespan (Figure 1B). This phenotype was more
severe in Rap1-deficient females, which showed a progressive
increase in body weight with time, reaching a 30% increase in
body weight compared to wild-type females at 80–90 weeks of
age (Figures 1A–1C). The increased body weight of Rap1/
adult mice (35–60 weeks old) cannot be attributed to differences
in daily food intake or output (Figure 1D, right panel). Indeed, at a
younger age (5 weeks old), Rap1/ females showed a signifi-
cantly lower food intake compared to wild-type controls (Fig-
ure 1D, left panel). Together, these findings indicate that Rap1
deletion leads to an early onset of obesity, which is more pro-
nounced in females than in males, and cannot be attributed to
a higher food intake.
We next determined whether increased body weight in Rap1-
deficient mice could be due to differences in energy expendi-
ture (EE). To this end, we performed indirect calorimetry analysis
in 8-to 12-week-old mice from both genotypes.We found no sig-
nificant differences between genotypes in EE, oxygen consump-
tion, or locomotor activity, both in males and females (Figures
1E, 1F, S1D, and S1E). Instead, we found a significant lower
respiratory exchange rate (RER) in Rap1-deficient females
compared to wild-type females in both light and dark cycles (Fig-
ure 1F). These differences could not be attributed to different
body contents because the ratio lean/fat was similar in both
groups of females as measured by nuclear magnetic resonance
(NMR) (Figure 1G). A lower RER suggests that more fat is being
used as energy source.
In order to assess whether there was an effect of Rap1 defi-
ciency in fatty acidmobilization, we analyzed circulating free fatty
acids and ketone bodies, the by-product of fatty acid oxidation
(Kersten et al., 1999). Interestingly, we found that young Rap1-
deficient females show significant higher levels of both free fatty
acids and ketone bodies compared to wild-type controls (Fig-
ure1G), in agreementwith the lowerRERvalues. This effect, how-
ever, was not observed in older females subjected to different
types of diets, whichwere obese (see Figure 4F). Plasma glucose
levels were similar between genotypes (Figure 1G).d state of young females (8–12 weeks old).
ned by the two-tailed Student’s t test. *p < 0.05; **p < 0.01, ***p < 0.001; ns, not
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Figure 2. Rap1-Deficient Mice Accumulate More Fat and Are Glucose Resistant
(A) Body weight, bonemineral density (BMD), leanmass, relative fat mass, and fat/lean ratio in 30-week-oldmice of the indicated gender and genotypemeasured
by DXA.
(B) Representative DXA images of wild-type and Rap1-deficient females.
(C) Organ weight-to-total body weight ratios. SF, subcutaneous fat; GF, gonadal fat; PRF, perirenal fat; BF, brown fat.
(D) Representative macroscopic images of the indicated tissues and organs.
(legend continued on next page)
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Rap1-Deficient Mice Accumulate More Fat in Visceral
Tissues and Show Signs of Liver Steatosis and
Inflammation
To determine the origin of the increased body weight, we per-
formed dual-energy X-ray absorptiometry (DXA), which allows
quantification of whole-body fat mass and of the fat-to-lean
ratio. We found that Rap1/ mice had a significant relative
increase in fat mass at 30 weeks of age in the absence of dif-
ferences in the bone mass index or in lean mass compared to
wild-type controls (Figures 2A and 2B). Fat accumulation was
more pronounced in Rap1-deficient females than in males (Fig-
ures 2A and 2B). In particular, at 30 weeks of age, Rap1-defi-
cient males and females presented a 34% and a 40% fat
mass relative to lean mass, respectively, compared to 25%
and 18% in age-matched wild-type males and females, respec-
tively. Similar results were obtained in older (55 weeks old) mice
(data not shown).
We confirmed these findings by determining the relative
weight of fat and lean in different tissues. We observed a signif-
icant increase in subcutaneous, gonadal, perirenal, and brown
fat mass relative to total body weight in Rap1-deficient females
compared to wild-type controls (Figures 2C and 2D). We did
not observe, however, significant differences in the weight of
liver, spleen, and kidney (Figures 2C and 2D). Of note, we noticed
accumulation of white fat also around brown fat in Rap1-defi-
cient mice, which was coincidental with larger intracellular lipid
droplets in brown fat tissues (Figures 2D and 2E). In addition,
F4/80 staining of liver and white fat sections showed more
abundant macrophage infiltrates in Rap1-deficient samples
compared to the wild-type controls (Figure 2E), indicative of
increased inflammation. Hematoxylin and eosin staining (H&E)
of white fat and liver sections revealed a larger size of adipocytes
and of hepatic lipid deposits, respectively (Figure 2E). Oil red O
staining of liver sections confirmed accumulation of large lipid
droplets suggestive of liver steatosis (Figure 2E). The oil red
O-stained area per section was significantly higher in Rap1-defi-
cient livers compared to wild-type controls (Figure 2F). Finally,
whereas we found similar amounts of liver triglycerides in young
(10 weeks old) females of both genotypes, older Rap1-deficient
females (35 weeks old) showed a significant 5-fold increase in
liver triglycerides compared to wild-type controls, further indica-
tive of liver steatosis (Figure 2G). The adipocyte mean area in
abdominal fat depots was also significantly larger in Rap1/
females compared to wild-type controls, indicating that fat accu-
mulation is due to both higher numbers and larger adipocytes
(Figure 2H).(E) Representative light microscopy images of H&E sections, F4/80 immunohistoc
tissues (scale bars, 100 mm).
(F) Quantification of oil red O-positive areas in liver sections of the indicated gen
(G) Quantification of triglyceride content in liver samples of young (10 weeks old
(H) Quantification of the adipocyte area in abdominal fat depots.
(I) GTT and ITT data of nine 40- to 50-week-old wild-type and Rap1 knockout fe
(J) Quantification of the area under the GTT curve (AUC), a.u., arbitrary units.
(K) Fasting glucose levels, fasting insulin levels, derived HOMA-IR insulin-resi
60-week-old females.
(L) Insulin levels of young females (10 weeks old) during fed and fasted states.
Error bars represent SD. Statistical significance was determined by two-tailed S
CRap1-Deficient Mice Are Glucose Resistant and Show
Some Signs of Metabolic Syndrome
To dissect the physiological defects leading to increased body
weight in Rap1-deficient mice, we tested their ability to respond
to glucose and insulin. To this end, we performed glucose and
insulin tolerance tests (GTTs and ITTs, respectively) on 35- to
50-week-old females. We found that Rap1-deficient females
are glucose resistant compared to wild-type controls but show
a normal response to exogenously administered insulin (Fig-
ure 2I). In particular, the area under the curve (AUC) values for
the GTT assays were significantly higher in Rap1-deficient
females compared with wild-type controls (Figure 2J). Analysis
of fasting glucose and insulin levels in a total of 16 mice per
genotype at 20–60 weeks of age showed significant higher levels
of both glucose and insulin in Rap1-deficient mice (Figure 2K).
The derived insulin resistance and insulin sensitivity indices,
homeostatic model assessment (HOMA-IR) and quantitative
insulin sensitivity check index (QUICKI), respectively, revealed
a worsened insulin resistance and decreased insulin sensitivity
in Rap1-deficient females (Figure 2K). Insulin levels were normal
in young 10-week-old females of both genotypes before the
onset of obesity, indicating that the glucose-resistance pheno-
type appears later in life concomitantly with the increased
body weight (Figure 2L).
In humans, increased body mass (i.e., central obesity), fatty
liver, and increased fasting plasma glucose levels are indicative
of metabolic syndrome, a condition associated with increased
visceral fat, inflammation, and severe cardiovascular problems
(Byrne et al., 2009). To address whether Rap1 deficiency was
leading to features of metabolic syndrome in mice, we per-
formed full histopathological analysis of Rap1-deficient females
at their time of death (Experimental Procedures). We observed
large accumulations of subcutaneous and abdominal fat, as
well as increased pericardial fat in Rap1-deficient females
compared to the wild-type controls (Figure 3A). Furthermore,
Rap1-deficient mice showed macrophage infiltrates in white
fat, brown fat, and in the liver, indicative of inflammation (Fig-
ure 3B). Lipidosis was also observed in kidneys, although to
a lower extent than in the liver (Figure 3B). Hepatic steatosis
in Rap1-deficient females was manifested by abundant and
large lipid deposits in liver sections that in some cases could
be readily detected macroscopically by the enlarged size and
pale-yellow appearance of the liver (Figures 3A and 3B).
Indeed, full histopathological analysis at the time of death
revealed that 50% of both male and female Rap1-deficient
mice showed severe hepatic steatosis and inflammation, ahemistry, oil red O staining, and UCP1 immunohistochemistry of the indicated
otypes.
) and adult (35 weeks old) females.
males.
stance quantification, and QUICKI insulin sensitivity quantification of 35- to
tudent’s t test. *p < 0.05; **p < 0.01; ***p < 0.001.
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Figure 3. Rap1-Deficient Mice Show Signs of Metabolic Syndrome and Cardiopathies at Death
(A) Representative images of (left) wild-type and (right) Rap1 knockout female bodies upon sacrifice at HEP. Mice were 80–90 weeks old. Note the dramatic
accumulation of subcutaneous, abdominal, and pericardial fat (magnification images of the heart at the sides) in Rap1 knockout females. Representative images
of liver samples are shown. Notice the fatty liver appearance of Rap1-deficient mice.
(B) Representative light microscopy images of H&E and red oil O-stained sections of the indicated organs of wild-type and knockout females at death. Note the
presence of macrophage infiltrates (black arrowheads) in Rap1-deficient white fat, brown fat, and liver compared to wild-type control tissues indicative of
(legend continued on next page)
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condition that is clinically known as nonalcoholic steatohepati-
tis (NASH) (Figure 3C). Centrilobular vein congestion was also
observed in Rap1-deficient livers indicative of cardiopatholo-
gies (Figure 3B) (Shibayama, 1987). Indeed, histopathological
heart examination revealed increased left ventricular diameter
and increased interventricular septum thickness in Rap1-defi-
cient mice (Figures 3D and 3E). Of note, we found a similar
mouse survival and normal tumor incidence in both genotypes
although males showed a trend towards a lower survival (Fig-
ure S1A–S1C and S2A). Together, these findings indicate that
Rap1-deficient mice develop pathologies, some of which are
reminiscent of those associated with metabolic syndrome in
humans.
Finally, we set out to address whether altered brown adipose
tissue (BAT) activity could also contribute to the phenotypes of
Rap1-deficient mice. BAT plays a role in total energy homeosta-
sis and body weight regulation by dissipating excess energy by
the so-called adaptive thermogenesis (Lowell et al., 1993). To
this end, we measured glucose uptake in brown fat by PET in
a set of adult wild-type and knockout animals. However, no
differences in glucose uptake between genotypes could be
detected, suggesting the absence of metabolic deregulation in
Rap1-deficient brown fat (Figures S2B and S2C).
High-Fat Diet Further Aggravates Obesity and Diabetes
in Rap1-Deficient Females
To further understand the origin of obesity and liver steatosis
associated with Rap1 deficiency, we subjected 4-week-old
Rap1+/+ and Rap1/ males and females to high-fat diet (HFD)
and followed weight gain in a longitudinal manner (weekly
measurements) (Experimental Procedures). In males, the HFD
resulted in a 10% increase in body weight compared to wild-
type controls, although the difference was not significant (Fig-
ure 4A). Interestingly, Rap1-deficient females showed a faster
rate of weight gain compared to wild-type controls from the start
of the treatment. In particular, 10 weeks after placement on a
HFD, Rap1-deficient females gained approximately 35% more
weight than wild-type females, and this difference was main-
tained or increased throughout the treatment (Figures 4A and
4B). In particular, whereas weight increase in wild-type females
fed a HFD was approximately 30% higher compared to wild-
type mice fed a standard diet, knockout females fed a HFD
presented as much as a 70% higher weight gain than wild-
type-females fed with a standard diet (Figures 4A and 4B). Inter-
estingly, Rap1-deficient females fed with a standard diet gained
weight at the same rate as wild-type females fed with a HFD (Fig-
ures 4A and 4B), suggesting that the magnitude of the metabolic
changes associated with Rap1 deficiency in female mice is
similar to those induced by a HFD. The increased body weightinflammatory lesions; note also the larger size of Rap1-deficient adipocytes as w
liver of Rap1-deficient mice presents symptoms of hepatic steatosis and centrilo
(C) Incidence of liver disease at time of death in wild-type and Rap1-deficient ma
fibrosis in some cases.
(D) Quantification of the left ventricular diameter (LVD) and the intraventricular se
(E) Representative images of wild-type and Rap1-deficient heart at death.
Error bars represent the SD. Statistical significance was determined by the two-
See also Figure S2.
Cof Rap1/ females fed a HFD could not be attributed to differ-
ences in daily food intake or output (Figure 4C).
Next, we performed GTTs and ITTs 20 weeks after placement
on a HFD in both genotypes. We found that Rap1-deficient
females are significantly more glucose resistant than wild-type
females on the same diet, whereas no significant differences
were observed in males (Figure 4D). In agreement with this, the
AUC values revealed a significantly worse glucose tolerance in
the Rap1-deficient females on a HFD compared to wild-type
controls on the same diet (Figure 4E). Upon injection of insulin,
HFD-fed animals were almost unresponsive to insulin not being
able to remove glucose from blood. However, both male and
female wild-type and Rap1-deficient mice showed similar ITT
curves (data not shown), indicating that HFD affects the
response to insulin independently of RAP1.
In order to further understand the metabolic effects of RAP1
abrogation, we analyzed a number of metabolic parameters in
the plasma of mice subjected to either a standard diet or a
HFD, in fed state or after 16 hr fasting (Figure 4F). We found
that Rap1-deficient females on both standard diet and HFD
showed significantly increased levels of alanine aminotrans-
ferase (ALT) compared to wild-type females, indicative of liver
dysfunction. Indeed, the ALT levels present in fasted Rap1-
deficient females on both diets correspond to a grade 2 of
hepatotoxicity (126–250 U/l) (Lenaerts et al., 2005). Of note,
Rap1-deficient females on a standard diet showed higher ALT
levels than wild-type controls on a HFD, again indicating the
magnitude of the metabolic defects associated with Rap1 defi-
ciency. Cholesterol levels were also significantly higher in fasted
Rap1-deficient females compared to wild-type controls on both
diets (Figure 4F). In the case of males, we did not find any differ-
ences between genotypes, although both ALT and cholesterol
levels were significantly elevated in mice on a HFD compared
to standard diet (Table S1).
No differences in the levels of free fatty acids, ketone bodies,
and triglycerides were found between genotypes (Figure 4F).
Similarly, no differences in the levels of lactate, creatinine, total
proteins, albumin, urea, phosphorous, and calcium between
both genotypes could be detected, indicating no kidney
dysfunction (Table S1).
Metabolic Alterations in Rap1-Deficient Tissues Occur
in the Absence of Changes in Telomere Length and in
the Absence of Telomere Damage
Telomere dysfunction owing to extreme telomere shortening is
proposed to induce metabolic and mitochondrial compromise
(Sahin et al., 2011). In particular, late-generation telomerase-defi-
cient mice show a p53-dependent transcriptional repression of
Pgc1a andPgc1b and the subsequent downregulation of severalell as the lipid deposits in brown fat, liver, and kidney (green arrowheads). The
bular vein congestion (blue arrowheads).
les and females. NASH includes severe steatosis and inflammation, as well as
ptum thickness (IST).
tailed Student’s t test. *p < 0.05; **p < 0.01, ***p < 0.001.
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Figure 4. Enhanced Weight Gain and Glucose Resistance in Rap1 Null Females Subjected to a HFD
(A) Weight curves of male and female mice of the indicated phenotypes on a standard diet (18% calories from fat) or HFD (45% calories from fat) commencing at
4 weeks of age.
(B) Representative images of female mice of the indicated genotype and age subjected to a HFD during 50 weeks and to a standard diet (‘‘SD’’; 60 weeks).
(C) Relative food intake and output values normalized by body weight monitored during a week period in metabolic cages in female mice subjected to a
standard diet.
(D) GTT data of wild-type and Rap1 knockout male (left) and female (right) mice after 20 weeks on a HFD.
(E) Quantification of the area under the GTT curve (AUC).
(F) Analysis of plasma parameters in wild-type and Rap1-deficient females on a standard diet (75–85 weeks old) and HFD (after 30 weeks on HFD). TG,
triglycerides; FFA, free fatty acids.
Error bars represent SD. Statistical significance was determined by two-tailed Student’s t test. *p < 0.05; **p < 0.01, ***p < 0.001.
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Figure 5. Rap1 Deficiency Does Not Lead to Changes in Telomere Length in Liver and in Brown Fat
(A) Total nuclear telomere fluorescence as determined by Q-FISH on tissue sections. Three 30-week-old females per genotype were used for the analysis. a.u.f.,
arbitrary units of fluorescence.
(B) qPCR validation of OXPHOS genes in liver samples. The results are normalized to wild-type samples. Three independent samples per genotype were
analyzed.
(C) Representative immunofluorescence images of liver sections from the indicated genotypes stained for gH2AX (green) and 53BP1 (red). Posthepatectomized
TRF1-deficient liver sections were used as positive controls for gH2AX and 53BP1. Scale bars, 50 mm.
Statistical significance was determined by two-tailed Student’s t test. Error bars represent SD.of their target genes (Nrf1, Erra, Tfam, and Ppara), as well as
downregulation of members of the oxidative phosphorylation
(OXPHOS) pathway (ATP synthase, cytochrome C, and cyto-
chrome C oxidase) (Sahin et al., 2011). In order to address
whether the metabolic changes observed in Rap1-deficient
mice could be the indirect consequence of defects in telomere
length homeostasis, we performed quantitative telomere fluores-
cence in situ hybridization (Q-FISH) analysis on liver and brown
fat sections from both genotypes. Telomere fluorescence was
similar in liver and brown fat tissues from both genotypes (Fig-Cure 5A), indicating that the metabolic changes associated with
Rap1 deficiency are not due to abnormal telomere length.
We next determined the expression levels of Pgc1b, p53,
Nrf1, Erra, Tfam, CytC, and ATPsyn by qPCR in liver tissue
from both genotypes (Figure 5B). In contrast to repression of
these genes in late-generation telomerase-deficient mice, we
did not find significant changes in their expression in Rap1-defi-
cient livers compared to controls (Figure 5B), in line with normal
telomere length in Rap1-deficient livers. Also in accordance with
normal telomere length, we did not find increased telomereell Reports 3, 2059–2074, June 27, 2013 ª2013 The Authors 2067
damage in liver as indicated by gH2AX and 53BP1stainning
(Figure 5C).
RAP1 Deficiency Affects Metabolic Transcriptional
Networks before the Onset of Obesity
We previously reported that RAP1 binds throughout chromo-
some arms where it is proposed to regulate transcription (Marti-
nez et al., 2010). In order to address whether obesity, diabetes,
and other metabolic phenotypes provoked by Rap1 deficiency
could be explained by defined transcriptional changes, we stud-
ied gene expression profiles of liver, gonadal white fat, and
gastrocnemius muscle from mice from both genotypes. To rule
out that the expression changes could be secondary to the
obesity phenotype, we performed the gene expression studies
before the onset of obesity. To this end, we used young females
(10 weeks old) with a similar mean body weight of around 19 g in
both genotypes. GSEA of liver showed alterations in many meta-
bolic pathways (Figure S3A; Table S2). In particular, fatty acid
metabolism, androgen and estrogen metabolism, biosynthesis
of steroids, pyruvate metabolism, and PPAR signaling pathway
were significantly deregulated in the liver of Rap1-deficient
females. In gonadal white fat, Rap1-deficient mice showed an
enrichment of inflammation/immunity and cell adhesion/cell-cell
interaction networks (Figure S3B; Table S3). Similarly, metabolic
pathways, such as OXPHOS and PPAR signaling pathways, also
showed an enriched signature in wild-type gonadal fat (Fig-
ure S3B; Table S3). In contrast, GSEA of muscle did not render
any significantly deregulated pathway, suggesting that the
RAP1-mediated metabolic phenotype does not stem from
transcriptional deregulation inmuscle (data not shown). In agree-
ment with this notion, we did not find differences in the abun-
dance of type I (high oxidative potential) and type II (low oxidative
potential) fibers in the gastrocnemiusmuscle (Lin et al., 2002).We
also found a similar succinate dehydrogenase (SDH) staining in
the gastrocnemius of young females (8 weeks old) from both ge-
notypes (Figures S2D and S2E), thus indicating that metabolic
phenotypes associated with Rap1 deficiency are not mediated
by the muscle.
We further confirmed deregulation of key metabolic pathways
in older females at the onset of obesity by using both transcrip-
tome and proteome analyses (Experimental Procedures). In
particular, we studied wild-type and Rap1-deficient females at
34weeks of age, withmean bodyweights of 24 and 36 g, respec-
tively. Differential gene expression analysis revealed that 671
probes deregulated, corresponding to 618 genes (false discov-
ery rate [FDR] <0.15) in Rap1-deficient liver (Table S4). Gene
Ontology (GO) analysis of the results showed a significant upre-
gulation of genes involved in different metabolic pathways
including the organic acid, lipid, fatty acid, steroid, cholesterol,
and carboxylic acid metabolism in Rap1-deficient livers (Table
S5). In addition, GSEA of Rap1-deficient livers showed alteration
of many metabolic pathways, including the branched chain
amino acid degradation, the PPAR signaling pathway, glyceroli-
pids, and fatty acid metabolism, which showed a highly signifi-
cant enrichment in Rap1-deficient livers (FDR <0.01), reflecting
alterations in lipid homeostasis. Several routes within carbohy-
drate metabolism such as glycolysis and gluconeogenesis as
well as diabetes pathways were also found deregulated (Table2068 Cell Reports 3, 2059–2074, June 27, 2013 ª2013 The AuthorsS6). Of interest, Rap1-deficient liver samples also showed
enrichment in gene sets involved in immune response pathways
and in cell adhesion and cell-cell interactions (i.e., ECM receptor
interaction and focal adhesion) (Table S6). By using qPCR in liver
samples, we validated some of the differentially expressed
genes involved in metabolism, including epidermal growth factor
receptor (Egfr), insulin-like growth factor-binding protein 2
(Igfbp2), leptin receptor (Lepr), and insulin growth factor 1 (Igf1)
(Figure S4A). We also found a 50% decrease in Pgc1a expres-
sion in the liver of Rap1-deficient mice, in agreement with previ-
ous results obtained with MEFs (Martinez et al., 2010).
Interestingly, when both the differentially expressed genes
(transcriptome) and proteins (iTRAQ) in liver samples from
female mice were analyzed by Ingenuity Systems Pathway
analysis (Ingenuity IPA software), we found the same top-ten
pathways affected in both sets of samples, namely fatty acid
metabolism, xenobiotic metabolism, glycolysis and gluconeo-
genesis, bile acid biosynthesis, tryptophan, propanoate, linoleic,
androgen/estrogen, pyruvate, and the metabolism of arachnoid
acid (Figure S4B). Notably, both types of analyses indicated
altered expression of a large number of PPARa target genes in
the Rap1-deficient obese females (Figure S5), pinpointing to
deregulation of PPARa as one of the key events associated
with Rap1 deficiency. In this regard, the PPAR signaling pathway
is known to regulate a plethora of genes important for diverse
cellular functions, including metabolism, cell proliferation, cell
differentiation, apoptosis, and immune response.
Decreased mRNA and Protein Expression of Ppara and
Pgc1a in Rap1-Deficient Livers
Given the key role of the PPAR pathway in the regulation of meta-
bolism together with the fact that this pathway was significantly
deregulated in liver and white fat from young Rap1-deficient
females before the onset of obesity, as well as in the obese
mice,wenext set out tostudy theexpressionof the threesubtypes
of PPARs, namely Ppara, Pparg, and Ppard/b, as well as their
cofactor Pgc1a, in both liver and gonadal white fat samples
from young 10-week-old female mice by using qPCR (Figure 6A).
No significant differences in Pparg and Ppard/b expression were
found between genotypes in both tissues at 10 weeks of age
(Figure 6A). Interestingly, the levels of Ppara (NCBI RefSeq NM_
011144) and Pgc1a were reduced by approximately 50% in liver
and white fat from Rap1-deficient mice compared to the controls
before the onset of obesity (Figure 6A). The levels of Ppara tran-
script variant 2 (Ppara-t2) (NCBI RefSeq NM_001113418) were
also significantly reduced in both tissues from Rap1-deficient
mice (Figure 6A).Byusingwesternblottinganalysis,weconfirmed
a 0.5-fold reduction in PPARa and PGC1a protein levels in liver
samples from Rap1-deficient mice (Figures 6B and 6C). These
results suggest that deregulation of PPARa/PGC1a is one of the
initial events that may trigger the transcriptional changes in both
liver and white fat leading to obesity in Rap1-deficient mice.
Defective Expression of PPARa Target Genes in Rap1-
Deficient Livers upon Fasting
Given the observed deregulated expression of Ppara and its
cofactor Pgc1a in Rap1-deficient tissues, we next set out to
address the expression of several known PPARa downstream
Figure 6. RAP1 Regulates Expression of
Ppara and Pgc1a
(A) qPCR analysis of the indicated genes in liver
and gonadal white fat from 10-week-old wild-type
and Rap1 knockout females. Results are normal-
ized to fed wild-type mean values.
(B) Western blotting analysis of PGC1a, PPARa,
and RAP1 protein levels in liver samples fromwild-
type and Rap1 knockout females.
(C) Quantification of PGC1a and PPARa protein
levels in liver. Results are normalized to wild-type
mean values.
(D) qPCR analysis of the indicated genes in liver
samples from 10-week-old wild-type and Rap1
knockout females, which were either fed or after
24 hr fasting. Themetabolic processes affected by
the analyzed genes are indicated. Results are
normalized to wild-type cells. Sample size (n) is
indicated in each case.
Error bars represent SD. Statistical significance
was determined by two-tailed Student’s t test. *p <
0.05; **p < 0.01.
See also Figures S3–S6.targets in young (10 weeks old; before the onset of obesity)
females of both genotypes, which were either fed or fasted for
24 hr. Fasting is known to downregulate transcription of lipo-
genic genes in the liver and to upregulate genes involved in
gluconeogenesis, lipid transport/uptake, and fatty acid oxida-
tion, in this manner ensuring an adequate supply of substrates
that can be metabolized by other tissues (Yoon et al., 2001). In
particular, Pgc1a expression is induced by fasting and serves
as a transcriptional booster to augment the capacity of meta-
bolic adaptation to activate gluconeogenesis and fatty acid
oxidation (Yoon et al., 2001). In contrast to the upregulation of
Ppara gene expression observed in fasted SV129wild-type (Ker-
sten et al., 1999), we did not observe differences in the Ppara
expression levels between fed and fasted states in our wild-
type mice (Figure 6D).Cell Reports 3, 2059–207Under nonfasting conditions, we
confirmed decreased expression of
Ppara and Pgc1a in liver samples from
10-week-old Rap1-deficient female
mice (Figure 6D). We also observed
decreased expression of a key regulator
of lipogenesis, the sterol regulatory
element-binding transcription factor 1
(Srebp1) (Figure 6D) (Horton et al.,
2002; Liang et al., 2002). Interestingly,
Ppara-deficient mice fed ad libitum also
show decreased expression of Srebp1c
(Hebbachi et al., 2008), in line with
decreased Ppara expression in Rap1-
deficient livers. Consistent with lower
levels of PPARa/PGC1a in Rap1-defi-
cient livers, we also observed decreased
levels of the PPARa/PGC1a downstream
targets SLC27a2 (solute carrier family
27) and CD36 (cluster of differentiation36), which are important to transfer fatty acids across the cell
membrane (Martin et al., 1997; Motojima et al., 1998; Rakh-
shandehroo et al., 2009). Finally, Rap1-deficient livers also
showed decreased expression of Cpt1 and Cpt2 (carnitine
palmitoyltransferase 1 and 2, respectively), which allow the
transport of long-chain acyl-coenzyme A (CoA) across the
inner mitochondrial membrane to enter the fatty acid b-oxida-
tion pathway (Kersten et al., 1999; Rakhshandehroo et al.,
2010) (Figure 6D). No differences were observed between
genotypes in key regulators of gluconeogenesis (phosphoenol
pyruvate carboxykinase [Pepck] and glucose-6-phosphatase
[G6Pase]) (Figure 6D). Together, these results indicate that
lipid accumulation in Rap1-deficient mice is likely to be the
consequence of a reduced capacity for fatty acid import and
utilization.4, June 27, 2013 ª2013 The Authors 2069
Upon fasting, we confirmed decreased liver transcription of
genes involved in lipogenesis (Srebp1; fatty acid synthase
[Fas]) and increased transcription of genes involved in gluconeo-
genesis (Pepck, G6Pase), lipid uptake (Cd36, Slc27a2), and
mitochondrial b-oxidation (medium-chain and very long-chain
acyl-CoA dehydrogenase, Acadm and Vlcad; as well as Cpt1a
and Cpt2) (Figure 6D) in mice of both genotypes. The induction
of PEPCK was lower in Rap1-deficient samples compared to
wild-type (Figure 6D). Similarly, the induction ofCpt1awas lower
in Rap1-deficient livers compared to wild-type controls (Fig-
ure 6D). Importantly, whereas the expression of Pgc1a was
increased upon fasting in wild-type livers, Rap1-deficient livers
failed to upregulate Pgc1a (Figure 6D), thus indicating a defec-
tive Pgc1a response in the liver as a consequence of fasting
associated with Rap1 deficiency.
In summary, gene expression profiling reveals that some
PPARa target genes are affected by Rap1 deletion in fed and
fasted states (i.e., Cpt1), others only in the fed state (i.e.,
Slc27a2, Cd36, and Cpt2), and others only in the fasted state
(i.e., Pepck). In contrast, the expression of other PPARa target
genes, such as Acadm, Vlcad, Fgf21, Cyp4a10, and Cyp4a14,
was not affected in Rap1-deficient mice in fed or fasted states
(Figures 6D and S6A). These resultsmay suggest thatRap1 dele-
tion does not fully abolish Ppara expression. On the other hand,
they may suggest the convergence of different regulatory path-
ways toward the regulation of the expression of a single PPARa
target gene.
In order to investigate whether RAP1 might regulate other
metabolically important hepatic transcription factors, we per-
formed gene expression profile analysis in liver samples of
young females (10 weeks old) that had been fasting for 24 hr.
Genes expressed in mouse liver were obtained from Barcode
server with a consensus proportion of 0.95 (McCall et al.,
2011). Transfac database annotations were employed to retrieve
those genes described as transcription factors. The resulting
gene set was tested by GSEA of Rap1-deficient versus wild-
type mice. GSEA rendered a nonsignificant FDR value (0.49),
demonstrating that this gene set was not deregulated in
Rap1/ livers. However, out of the 66 transcription factors
tested, Pgc1a was the most downregulated in Rap1/ liver
compared to wild-type liver, being located in the first position
of the wild-type side of GSEA ranking and showing the highest
absolute values for the enrichment score and the log fold
change (Figure S6B). These results underscore the specificity
of RAP1 in the regulation of PPARa/PGC1a axis in the liver,
which cannot be extended to every hepatic transcription factor.
RAP1 Binds to Ppara and Pgc1a Loci
By using ChIP-seq in wild-type and Rap1-deficient MEFs, we
previously demonstrated that RAP1 binds to intragenic sites
within the Pgc1a and Ppara genes (Martinez et al., 2010) (this
site is referred to as F3 in Figure 7A) (see Table S7 for genomic
coordinates). To address whether RAP1 binds to these sites
also in the liver, we performed ChIP analysis in Rap1-deficient
and wild-type freshly isolated liver samples using an anti RAP1
antibody (Experimental Procedures). ChIP analysis followed by
qPCR in fresh liver samples demonstrated that RAP1 binds to
the intragenic F3 region in Ppara and Pgc1a genes in the liver.2070 Cell Reports 3, 2059–2074, June 27, 2013 ª2013 The AuthorsIn addition to the peaks identified by ChIP-seq, we also tested
RAP1 binding to Ppara and Pgc1a promoter regions. In partic-
ular, upon browsing Ppara and Pgc1a upstream regulatory
regions around the transcription start site (TSS), we identified a
region (F1, Figures 7A and S7) in both genes that was enriched
in regulatory elements (Rosenbloom et al., 2013) and designed
primers to amplify two fragments within F1 (F1-a and F1-b)
(Experimental Procedures). qPCR on the immunoprecipitated
DNA showed that RAP1 also binds to F1-a in Pgc1a promoter.
RAP1 binding, however, was not detected at F1-b in Pgc1a pro-
moter or the F1-a/F1-b in Ppara promoter (Figure 7A). These
results indicate that RAP1 is recruited to Ppara and Pgc1a loci,
supporting thatRap1 is involved in their transcriptional regulation.
RAP1 Regulates Ppara and Pgc1a Transcription
To address whether RAP1 is involved in Ppara and Pgc1a tran-
scriptional regulation, we cloned different DNA fragments
belonging to the Ppara (F3 in Figure 7A; FigureS7) and Pgc1a
loci (F1–F4 in Figure 7A; Figure S7) upstream of a minimal pro-
moter driving luciferase expression (Experimental Procedures).
F3 in Ppara locus corresponded to previously identified RAP1-
binding peaks by ChIP-seq analysis (Martinez et al., 2010). F1
and F2 in Pgc1a locus corresponded to the Pgc1a promoter
region, and F3 and F4 corresponded to previously identified
RAP1-binding peaks byChIP-seq analysis (Martinez et al., 2010),
one located in intron 2 within Pgc1a ORF (F3) and the other
located 6.5 kb downstream the Pgc1a gene (F4) (Figures 7A
and 7B; Table S7). The different constructswere then transfected
into Rap1+/+ and Rap1/ LT-immortalized MEFs, and luciferase
activity was measured after 48 hr (Figure 7B). Interestingly,
luciferase activity was significantly decreased in Rap1/ cells
compared to wild-type cells transfected with Ppara-F3 and
Pgc1a-F1, which were found to contain a RAP1-binding site by
ChIP assay (Figure 7A). No differences were observed in F2–F4,
with the empty vector or with the vector harboring a genomic
fragment used as negative control (Figure 7B). A fragment within
the Hic1 locus previously shown to contain RAP1-dependent
enhancer activity was used as positive control (Martinez et al.,
2010). These results suggest that Ppara-F3 and Pgc1a-F1 have
RAP1-dependent enhancer activity and strongly suggest a role
for RAP1 in Ppara and Pgc1a transcriptional regulation.
We previously showed that Rap1-deficient MEFs have a
decreased Pgc1a expression (Martinez et al., 2010). To demon-
strate that decreased PGC1a and PPARa levels are due to Rap1
deficiency, a Rap1-containing vector was transfected into
immortalized wild-type and Rap1-deficient MEFs. A GFP-con-
taining vector was also transfected as negative control as well
as to estimate transfection efficiency. The expression levels of
Pppara and Pgc1a were then determined 48 hr after transfec-
tion. We found a significant recovery in Pppara and Pgc1a tran-
scription levels in Rap1-deficient MEFs upon RAP1 transgenic
expression, indicating a direct role of RAP1 in the transcriptional
regulation of these genes (Figure 7C).
DISCUSSION
By generating a whole-body Rap1-deficient mouse model, we
show here that the mammalian telomere-binding protein RAP1
Figure 7. RAP1 Protects from Obesity
through Regulating the Expression of Ppara
and Pgc1a
(A) ChIP of RAP1 and qPCR of different genomic
DNA regions of Ppara and Pgc1a loci in wild-type
and Rap1/ liver samples. A schematic repre-
sentation of the analyzed fragments is depicted.
F1 and F2 in Ppara and in Pgc1a loci were chosen
based on the observed enrichment in regulatory
elements in the upstream regulatory region of each
gene (see Figure S7). F1-a and F1-b refer to
different parts of F1. F3 and F4 in Ppara and in
Pgc1a contain RAP1-binding peaks previously
identified by ChIP-seq analysis (Martinez et al.,
2010). Values correspond to the ratio between the
percent immunoprecipitated DNA with respect to
the input in the wild-type and Rap1/ liver sam-
ples. Three independent mice were analyzed per
genotype.
(B) Luciferase activity in wild-type and Rap1
knockout LT-immortalized MEFs. A genomic
fragment within Ppara-coding sequence (F3), two
genomic fragments within the Pgc1a promoter
(F1 and F2), one fragment located in a Pgc1a
intron (F3), and other fragments downstream the
Pgc1a gene (F4) were cloned upstream of a
minimal promoter driving luciferase expression
(schematic representation as in A). A genomic
fragment within the Hic1 locus and an aleatory-
chosen genomic fragment not identified in ChIP-
seq were used as positive and negative control,
respectively (Martinez et al., 2010). The con-
structs were subsequently transfected into LT-
immortalized MEFs. Results were normalized to
the activity obtained in cells transfected with the
empty vector.
(C) Rap1 transgenic expression in Rap1/
immortalized MEFs rescues Pgc1a and Ppara
expression. LT-immortalizedRap1+/+ andRap1/
MEFs were electrophorated with PTT3-RAP1 vector and with the vector harboring GFP as a negative control. Results are normalized with regards to expression
levels in cells expressing GFP.
Error bars represent SD. Statistical significance was determined by two-tailed Student’s t test. *p < 0.05; **p < 0.01; ***p < 0.001.
See also Figure S7.is dispensable for mouse development and adult viability, in
contrast to that previously reported by Teo et al. (2010) and in
agreement with Sfeir et al. (2010). In agreement with our previous
findings that RAP1 binds throughout chromosome arms (Marti-
nez et al., 2010), we find a role for RAP1 in the transcrip-
tional regulation of pathways involved in postnatal cellular
energy metabolism. In line with this, adult Rap1-deficient mice
are obese and show abnormal accumulation of fat in abdom-
inal tissues, concomitant with hepatic steatosis and glucose
resistance.
In particular, by using both gene expression and iTRAQ anal-
ysis of Rap1-deficient liver and white fat tissues, we find a signif-
icant deregulation of the PPAR signaling pathway, a key player in
the regulation of energy homeostasis. By usingChIP analysis, we
further demonstrate that RAP1 binds to Ppara and Pgc1a loci in
liver, and that can regulate transcription of Ppara and Pgc1a. In
line with this, Rap1-deficient mice show decreased Ppara and
Pgc1a expression and the subsequent deregulation of some
of their target genes, leading to severe metabolic alterationsCthat are in accordance with the early onset of obesity found in
these mice.
We show here that Rap1-deficient mice also develop hepatic
steatosis. In this regard, the PPARa/PGC1a complex is a key
regulator of fatty acid oxidation (Kersten et al., 1999; Leone
et al., 1999, 2005). CPT1, a target of PPARa/PGC1a, constitutes
the rate-limiting step in fatty acid oxidation (Djouadi et al., 1998).
Our results show thatCpt1a andCpt2 expression is decreased in
Rap1-deficient livers compared to wild-type controls, suggest-
ing that Rap1-deficient mice are defective in fatty acid catabo-
lism. Oxidation of fatty acids in the liver is also tightly coupled
to glucose synthesis (Yoon et al., 2001). In fasted animals, we
find that the expression of the key gluconeogenic enzyme,
PEPCK, is decreased in Rap1-deficient mice. Similarly, the
expression of several fatty acid transporters, SLC27a2 and
CD36, is also significantly decreased in Rap1-deficient livers.
In summary, these findings place RAP1 as a key factor in the
physiologic regulation of lipid homeostasis, through the
PPARa/PGC1a regulatory pathway.ell Reports 3, 2059–2074, June 27, 2013 ª2013 The Authors 2071
Further supporting a role for RAP1 in modulating PPARa/
PGC1a, the phenotypes of Rap1-deficient mice are strikingly
similar to those of Ppara-deficient mice. In particular, similar to
Rap1 deficiency, PPARa deficiency leads to a late onset of spon-
taneous obesity with a remarkable sexual dimorphism. As in the
case of Rap1 deficiency, PPARa abrogation leads to a more
pronounced obesity phenotype in females than in males,
although males also develop hepatic steatosis (Costet et al.,
1998; Lee et al., 1995). Moreover, female mice deficient in
PGC1a, the PPARa cofactor, also show increased body weight
(Leone et al., 2005). Interestingly, it has been shown that PPARa
has broad female-dependent repressive actions on hepatic
genes involved in steroidmetabolism and immunity. In particular,
specific gene sets involved in steroid metabolism, as well as
androgen and estrogen metabolism, have been shown to exhibit
PPARa-dependent sexual dimorphism (Leuenberger et al.,
2009). These genes are upregulated in PPARa-deficient females
but remained unchanged in PPARa-null males compared to
wild-type controls. We find here that the same pathways are
upregulated in the liver of Rap1-deficient females compared to
wild-type females (see Table S2), strongly supporting a role of
RAP1 in sex-specific PPARa functions.
Telomere shortening in the context of telomerase-deficient
mice was previously shown to repress Pgc1a/b and its
downstream transcriptional network, leading to mitochondrial
dysfunction (i.e., compromised OXPHOS and respiration,
decreased ATP generation capacity, and increased oxidative
stress). In particular, short/dysfunctional telomeres lead to
increased p53 levels, which can bind to Pgc1a and Pgc1b
promoters and repress their transcriptional expression (Sahin
et al., 2011). In the setting of the severe metabolic changes
induced by RAP1 deficiency, however, we did not observe the
presence of short/dysfunctional telomeres in liver or brown fat,
indicating that metabolic changes associated with RAP1 defi-
ciency are independent of telomere dysfunction. This is further
supported by clearly distinct mouse phenotypes associated
with either telomerase deficiency or RAP1 deficiency. Telome-
rase-deficient mice show a dramatic reduction in lifespan, lower
body weight, and decreased fat mass (Herrera et al., 1999; Lee
et al., 1998; Sahin et al., 2011). In contrast, Rap1 knockout
mice show an obese phenotype and no differences in survival
curves as compared to wild-type controls.
In conclusion, we demonstrate here that RAP1 serves as a
transcriptional regulator that controls the capacity of down-
stream metabolic pathways critical for metabolic maturation. In
its absence, female mice develop obesity, glucose intolerance,
and hepatic steatosis. We propose that the Rap1 null mutant
mouse should serve as a useful murine model for studying the
role of altered energy metabolism in obesity, diabetes, and
hepatosteatosis.
EXPERIMENTAL PROCEDURES
Generation of Whole-Body Rap1 Knockout Mice
Rap1 knockout mice, Rap1/, were generated by crossing Rap1flox/flox mice
(Martinez et al., 2010) with a transgenic mouse line carrying the cre recombi-
nase under the control of the adenovirus EIIa promoter, EIIA-cre mice (Lakso
et al., 1996). Intercrosses to heterozygous Rap1+/ mice not harboring the
EIIA-cre allele resulted in the removal of the EIIA-cre allele in the mouse colony2072 Cell Reports 3, 2059–2074, June 27, 2013 ª2013 The Authorsarising from amplification. The genetic background of the mice was C57BL6/
129SV (90%/10%). All mice were generated and maintained at the Animal
Facility of the Spanish National Cancer Research Centre (CNIO) under specific
pathogen-free conditions in accordance with the recommendation of the
Federation of European Laboratory Animal Science Associations.
Mice were fed either a standard chow diet (Harlan Teklad 2018; 18% calo-
ries from fat) or, when indicated, a HFD (Research Diets D12451; 45% of total
calories from fat) starting at 4 weeks of age. Trained personnel performed
weekly observations of all mice. Upon detection of signs of morbidity, mice
were closely inspected daily until application of Humane End Point criteria
(http://dels.nas.edu/global/ilar/Guide).
Serum Analysis
Glucose in serum was measured using Glucocard strips (A. Meranini Diag-
nostics). Insulin levels were determined by ELISA (Ultra Sensitive Mouse
Insulin ELISA kit; Crystal Chem). Insulin sensitivity was evaluated by the
HOMA-IR (fasting insulin [mU/ml] 3 fasting glucose [mg/dl]/405) and the
QUICKI (1/(log(fasting insulin [mU/ml]) + log(fasting glucose [mg/dl]). Serum
ALT, cholesterol, triglycerides, bilirubin, urea, creatinine, albumin, total pro-
teins, lactate, phosphorous, and glucose were determined using ABX Pentra
(Horiba Medical). Plasma-free fatty acid and ketone body levels were
analyzed by in vitro enzymatic colorimetric method assays (NEFA-HR and
Autokit 3-HB kits, respectively; Wako Chemicals). To perform the GTT and
ITT, mice were i.p. injected, respectively, with 2 g of glucose/kg of body
weight and 0.75 IU insulin/kg of body weight (Eli Lilly; Humalog Insulin).
Tail blood glucose levels were measured with a glucometer at the required
times after injection. Prior to the GTT, mice were subjected to 8 hr of fasting.
Triglyceride content in liver samples was determined by colorimetric assay
kit (Cayman Chemical).
Gene Expression Analysis
Total RNA samples from liver and white fat tissues were analyzed on Agilent’s
Mouse Genome DNA microarray following the manufacturer’s instructions.
Images were quantified using Agilent Feature Extraction Software (v.10.1.1).
Luciferase and ChIP Assays
Luciferase assay and ChIP assays were performed as previously described
(Martinez et al., 2010).
ACCESSION NUMBERS
The microarray data sets have been deposited in the GEO database under
accession numbers GEO43171, GEO43172, GEO43173, and GEO43174.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, seven
figures, and seven tables and can be found with this article online at http://dx.
doi.org/10.1016/j.celrep.2013.05.030.
LICENSING INFORMATION
This is an open-access article distributed under the terms of the Creative
Commons Attribution-NonCommercial-No Derivative Works License, which
permits non-commercial use, distribution, and reproduction in any medium,
provided the original author and source are credited.
ACKNOWLEDGMENTS
We are indebted to S. West for RAP1 antibodies, R. Serrano for animal care,
L.E. Donate for editing support, and D. Pisano for bioinformatic support.
Research in the M.A.B. lab was funded by European Research Council Project
TEL STEM CELL (GA#232854), European Union FP7 Projects 2007-A-20088
(MARK-AGE) and 2010-259749 (EuroBATS), Spanish Ministry of Economy
and Competitiveness Projects SAF2008-05384 and CSD2007-00017,
Regional of Government of Madrid Project S2010/BMD-2303 (ReCaRe), AXA
Research Fund (Life Risks Project), the Lilly 2010 Preclinical Biomedicine
Research Award (Fundacio´n Lilly, Spain), and the Fundacio´n Botı´n (Spain).
M.A.B. conceived the original idea; M.A.B. and P.M. designed experiments
and wrote the manuscript; P.M. performed most of the experiments; G.G.-L.
performed the microarray analysis and FG de iTRAQ experiment; E.M.,
S.M., and R.d.C. carried out the indirect calorimetry measurements; and
J.M.F. performed the pathology analyses.
Received: December 18, 2012
Revised: March 30, 2013
Accepted: May 20, 2013
Published: June 20, 2013
REFERENCES
Akiyama, T.E., Nicol, C.J., Fievet, C., Staels, B., Ward, J.M., Auwerx, J., Lee,
S.S., Gonzalez, F.J., and Peters, J.M. (2001). Peroxisome proliferator-acti-
vated receptor-alpha regulates lipid homeostasis, but is not associated with
obesity: studies with congenic mouse lines. J. Biol. Chem. 276, 39088–39093.
Blasco, M.A. (2007). The epigenetic regulation of mammalian telomeres. Nat.
Rev. Genet. 8, 299–309.
Buchman, A.R., Kimmerly, W.J., Rine, J., and Kornberg, R.D. (1988). Two
DNA-binding factors recognize specific sequences at silencers, upstream
activating sequences, autonomously replicating sequences, and telomeres
in Saccharomyces cerevisiae. Mol. Cell. Biol. 8, 210–225.
Byrne, C.D., Olufadi, R., Bruce, K.D., Cagampang, F.R., and Ahmed, M.H.
(2009). Metabolic disturbances in non-alcoholic fatty liver disease. Clin. Sci.
116, 539–564.
Capieaux, E., Vignais, M.L., Sentenac, A., and Goffeau, A. (1989). The yeast
H+-ATPase gene is controlled by the promoter binding factor TUF. J. Biol.
Chem. 264, 7437–7446.
Carmen, A.A., Milne, L., and Grunstein, M. (2002). Acetylation of the yeast his-
tone H4 N terminus regulates its binding to heterochromatin protein SIR3.
J. Biol. Chem. 277, 4778–4781.
Celli, G.B., and de Lange, T. (2005). DNA processing is not required for ATM-
mediated telomere damage response after TRF2 deletion. Nat. Cell Biol. 7,
712–718.
Chen, Y., Yang, Y., van Overbeek, M., Donigian, J.R., Baciu, P., de Lange, T.,
and Lei, M. (2008). A shared docking motif in TRF1 and TRF2 used for differ-
ential recruitment of telomeric proteins. Science 319, 1092–1096.
Chin, L., Artandi, S.E., Shen, Q., Tam, A., Lee, S.L., Gottlieb, G.J., Greider,
C.W., and DePinho, R.A. (1999). p53 deficiency rescues the adverse effects
of telomere loss and cooperates with telomere dysfunction to accelerate carci-
nogenesis. Cell 97, 527–538.
Costet, P., Legendre, C., More´, J., Edgar, A., Galtier, P., and Pineau, T. (1998).
Peroxisome proliferator-activated receptor alpha-isoform deficiency leads to
progressive dyslipidemia with sexually dimorphic obesity and steatosis.
J. Biol. Chem. 273, 29577–29585.
d’Adda di Fagagna, F., Reaper, P.M., Clay-Farrace, L., Fiegler, H., Carr, P.,
Von Zglinicki, T., Saretzki, G., Carter, N.P., and Jackson, S.P. (2003). A DNA
damage checkpoint response in telomere-initiated senescence. Nature 426,
194–198.
de Lange, T. (2005). Shelterin: the protein complex that shapes and safeguards
human telomeres. Genes Dev. 19, 2100–2110.
Djouadi, F., Weinheimer, C.J., Saffitz, J.E., Pitchford, C., Bastin, J., Gonzalez,
F.J., and Kelly, D.P. (1998). A gender-related defect in lipid metabolism and
glucose homeostasis in peroxisome proliferator- activated receptor alpha-
deficient mice. J. Clin. Invest. 102, 1083–1091.
Hebbachi, A.M., Knight, B.L., Wiggins, D., Patel, D.D., and Gibbons, G.F.
(2008). Peroxisome proliferator-activated receptor alpha deficiency abolishes
the response of lipogenic gene expression to re-feeding: restoration of the
normal response by activation of liver X receptor alpha. J. Biol. Chem. 283,
4866–4876.CHecht, A., Laroche, T., Strahl-Bolsinger, S., Gasser, S.M., and Grunstein, M.
(1995). Histone H3 and H4 N-termini interact with SIR3 and SIR4 proteins: a
molecular model for the formation of heterochromatin in yeast. Cell 80,
583–592.
Herrera, E., Samper, E., Martı´n-Caballero, J., Flores, J.M., Lee, H.W., and
Blasco, M.A. (1999). Disease states associated with telomerase deficiency
appear earlier in mice with short telomeres. EMBO J. 18, 2950–2960.
Horton, J.D., Goldstein, J.L., and Brown, M.S. (2002). SREBPs: transcriptional
mediators of lipid homeostasis. Cold Spring Harb. Symp. Quant. Biol. 67,
491–498.
Imai, S., Armstrong, C.M., Kaeberlein, M., and Guarente, L. (2000). Transcrip-
tional silencing and longevity protein Sir2 is an NAD-dependent histone deace-
tylase. Nature 403, 795–800.
Karlseder, J., Broccoli, D., Dai, Y., Hardy, S., and de Lange, T. (1999). p53- and
ATM-dependent apoptosis induced by telomeres lacking TRF2. Science 283,
1321–1325.
Kersten, S., Seydoux, J., Peters, J.M., Gonzalez, F.J., Desvergne, B., and
Wahli, W. (1999). Peroxisome proliferator-activated receptor alpha mediates
the adaptive response to fasting. J. Clin. Invest. 103, 1489–1498.
Kersten, S., Desvergne, B., andWahli, W. (2000). Roles of PPARs in health and
disease. Nature 405, 421–424.
Kidani, Y., and Bensinger, S.J. (2012). Liver X receptor and peroxisome prolif-
erator-activated receptor as integrators of lipid homeostasis and immunity.
Immunol. Rev. 249, 72–83.
Kim, B.H., Won, Y.S., Kim, E.Y., Yoon, M., Nam, K.T., Oh, G.T., and Kim,
D.Y. (2003). Phenotype of peroxisome proliferator-activated receptor-
alpha(PPARalpha)deficient mice on mixed background fed high fat diet.
J. Vet. Sci. 4, 239–244.
Kim, S.H., Beausejour, C., Davalos, A.R., Kaminker, P., Heo, S.J., and Cam-
pisi, J. (2004). TIN2 mediates functions of TRF2 at human telomeres. J. Biol.
Chem. 279, 43799–43804.
Kyrion, G., Liu, K., Liu, C., and Lustig, A.J. (1993). RAP1 and telomere structure
regulate telomere position effects in Saccharomyces cerevisiae. Genes Dev.
7(7A), 1146–1159.
Lakso, M., Pichel, J.G., Gorman, J.R., Sauer, B., Okamoto, Y., Lee, E., Alt,
F.W., andWestphal, H. (1996). Efficient in vivomanipulation of mouse genomic
sequences at the zygote stage. Proc. Natl. Acad. Sci. USA 93, 5860–5865.
Lee, S.S., Pineau, T., Drago, J., Lee, E.J., Owens, J.W., Kroetz, D.L., Fernan-
dez-Salguero, P.M., Westphal, H., and Gonzalez, F.J. (1995). Targeted disrup-
tion of the alpha isoform of the peroxisome proliferator-activated receptor
gene in mice results in abolishment of the pleiotropic effects of peroxisome
proliferators. Mol. Cell. Biol. 15, 3012–3022.
Lee, H.W., Blasco, M.A., Gottlieb, G.J., Horner, J.W., 2nd, Greider, C.W., and
DePinho, R.A. (1998). Essential role of mouse telomerase in highly proliferative
organs. Nature 392, 569–574.
Lefebvre, P., Chinetti, G., Fruchart, J.C., and Staels, B. (2006). Sorting out the
roles of PPAR alpha in energy metabolism and vascular homeostasis. J. Clin.
Invest. 116, 571–580.
Lenaerts, A.J., Johnson, C.M., Marrieta, K.S., Gruppo, V., and Orme, I.M.
(2005). Significant increases in the levels of liver enzymes in mice treated
with anti-tuberculosis drugs. Int. J. Antimicrob. Agents 26, 152–158.
Leone, T.C., Weinheimer, C.J., and Kelly, D.P. (1999). A critical role for the
peroxisome proliferator-activated receptor alpha (PPARalpha) in the cellular
fasting response: the PPARalpha-null mouse as amodel of fatty acid oxidation
disorders. Proc. Natl. Acad. Sci. USA 96, 7473–7478.
Leone, T.C., Lehman, J.J., Finck, B.N., Schaeffer, P.J., Wende, A.R., Boudina,
S., Courtois, M., Wozniak, D.F., Sambandam, N., Bernal-Mizrachi, C., et al.
(2005). PGC-1alpha deficiency causes multi-system energy metabolic
derangements: muscle dysfunction, abnormal weight control and hepatic
steatosis. PLoS Biol. 3, e101.
Leuenberger, N., Pradervand, S., and Wahli, W. (2009). Sumoylated
PPARalpha mediates sex-specific gene repression and protects the liver
from estrogen-induced toxicity in mice. J. Clin. Invest. 119, 3138–3148.ell Reports 3, 2059–2074, June 27, 2013 ª2013 The Authors 2073
Li, B., and de Lange, T. (2003). Rap1 affects the length and heterogeneity of
human telomeres. Mol. Biol. Cell 14, 5060–5068.
Li, B., Oestreich, S., and de Lange, T. (2000). Identification of human Rap1:
implications for telomere evolution. Cell 101, 471–483.
Liang, G., Yang, J., Horton, J.D., Hammer, R.E., Goldstein, J.L., and Brown,
M.S. (2002). Diminished hepatic response to fasting/refeeding and liver
X receptor agonists in mice with selective deficiency of sterol regulatory
element-binding protein-1c. J. Biol. Chem. 277, 9520–9528.
Lin, J., Wu, H., Tarr, P.T., Zhang, C.Y., Wu, Z., Boss, O., Michael, L.F., Puig-
server, P., Isotani, E., Olson, E.N., et al. (2002). Transcriptional co-activator
PGC-1 alpha drives the formation of slow-twitch muscle fibres. Nature 418,
797–801.
Lowell, B.B., S-Susulic, V., Hamann, A., Lawitts, J.A., Himms-Hagen, J.,
Boyer, B.B., Kozak, L.P., and Flier, J.S. (1993). Development of obesity in
transgenic mice after genetic ablation of brown adipose tissue. Nature 366,
740–742.
Marcand, S., Gilson, E., and Shore, D. (1997). A protein-counting mechanism
for telomere length regulation in yeast. Science 275, 986–990.
Martin, G., Schoonjans, K., Lefebvre, A.M., Staels, B., and Auwerx, J. (1997).
Coordinate regulation of the expression of the fatty acid transport protein and
acyl-CoA synthetase genes by PPARalpha and PPARgamma activators.
J. Biol. Chem. 272, 28210–28217.
Martı´nez, P., and Blasco, M.A. (2010). Role of shelterin in cancer and aging.
Aging Cell 9, 653–666.
Martı´nez, P., and Blasco, M.A. (2011). Telomeric and extra-telomeric roles for
telomerase and the telomere-binding proteins. Nat. Rev. Cancer 11, 161–176.
Martinez, P., Thanasoula, M., Carlos, A.R., Go´mez-Lo´pez, G., Tejera, A.M.,
Schoeftner, S., Dominguez, O., Pisano, D.G., Tarsounas, M., and Blasco,
M.A. (2010). Mammalian Rap1 controls telomere function and gene expression
through binding to telomeric and extratelomeric sites. Nat. Cell Biol. 12,
768–780.
McCall, M.N., Uppal, K., Jaffee, H.A., Zilliox, M.J., and Irizarry, R.A. (2011). The
Gene Expression Barcode: leveraging public data repositories to begin cata-
loging the human andmurine transcriptomes. Nucleic Acids Res. 39(Database
issue), D1011–D1015.
Motojima, K., Passilly, P., Peters, J.M., Gonzalez, F.J., and Latruffe, N. (1998).
Expression of putative fatty acid transporter genes are regulated by peroxi-
some proliferator-activated receptor alpha and gamma activators in a tissue-
and inducer-specific manner. J. Biol. Chem. 273, 16710–16714.
Palm, W., and de Lange, T. (2008). How shelterin protects mammalian telo-
meres. Annu. Rev. Genet. 42, 301–334.
Rakhshandehroo, M., Hooiveld, G., Mu¨ller, M., and Kersten, S. (2009).
Comparative analysis of gene regulation by the transcription factor PPARalpha
between mouse and human. PLoS One 4, e6796.
Rakhshandehroo, M., Knoch, B., Mu¨ller, M., and Kersten, S. (2010). Peroxi-
some proliferator-activated receptor alpha target genes. PPAR Res. 2010,
612089.2074 Cell Reports 3, 2059–2074, June 27, 2013 ª2013 The AuthorsRosenbloom, K.R., Sloan, C.A., Malladi, V.S., Dreszer, T.R., Learned, K.,
Kirkup, V.M., Wong, M.C., Maddren, M., Fang, R., Heitner, S.G., et al.
(2013). ENCODE data in the UCSC Genome Browser: year 5 update. Nucleic
Acids Res. 41(Database issue), D56–D63.
Sahin, E., Colla, S., Liesa, M., Moslehi, J., Mu¨ller, F.L., Guo, M., Cooper, M.,
Kotton, D., Fabian, A.J., Walkey, C., et al. (2011). Telomere dysfunction
induces metabolic and mitochondrial compromise. Nature 470, 359–365.
Sanderson, L.M., Boekschoten, M.V., Desvergne, B., Mu¨ller, M., and Kersten,
S. (2010). Transcriptional profiling reveals divergent roles of PPARalpha and
PPARbeta/delta in regulation of gene expression in mouse liver. Physiol.
Genomics 41, 42–52.
Sfeir, A., Kabir, S., van Overbeek, M., Celli, G.B., and de Lange, T. (2010). Loss
of Rap1 induces telomere recombination in the absence of NHEJ or a DNA
damage signal. Science 327, 1657–1661.
Shibayama, Y. (1987). The role of hepatic venous congestion and endotoxae-
mia in the production of fulminant hepatic failure secondary to congestive
heart failure. J. Pathol. 151, 133–138.
Shore, D., and Nasmyth, K. (1987). Purification and cloning of a DNA binding
protein from yeast that binds to both silencer and activator elements. Cell
51, 721–732.
Takai, H., Smogorzewska, A., and de Lange, T. (2003). DNA damage foci at
dysfunctional telomeres. Curr. Biol. 13, 1549–1556.
Tanny, J.C., Dowd, G.J., Huang, J., Hilz, H., and Moazed, D. (1999). An enzy-
matic activity in the yeast Sir2 protein that is essential for gene silencing. Cell
99, 735–745.
Tejera, A.M., Stagno d’Alcontres, M., Thanasoula, M., Marion, R.M., Martinez,
P., Liao, C., Flores, J.M., Tarsounas, M., and Blasco, M.A. (2010). TPP1 is
required for TERT recruitment, telomere elongation during nuclear reprogram-
ming, and normal skin development in mice. Dev. Cell 18, 775–789.
Teo, H., Ghosh, S., Luesch, H., Ghosh, A., Wong, E.T., Malik, N., Orth, A., de
Jesus, P., Perry, A.S., Oliver, J.D., et al. (2010). Telomere-independent Rap1 is
an IKK adaptor and regulates NF-kappaB-dependent gene expression. Nat.
Cell Biol. 12, 758–767.
van Steensel, B., Smogorzewska, A., and de Lange, T. (1998). TRF2 protects
human telomeres from end-to-end fusions. Cell 92, 401–413.
Yang, X., Figueiredo, L.M., Espinal, A., Okubo, E., and Li, B. (2009). RAP1 is
essential for silencing telomeric variant surface glycoprotein genes in Trypano-
soma brucei. Cell 137, 99–109.
Ye, J.Z., Hockemeyer, D., Krutchinsky, A.N., Loayza, D., Hooper, S.M., Chait,
B.T., and de Lange, T. (2004). POT1-interacting protein PIP1: a telomere length
regulator that recruits POT1 to the TIN2/TRF1 complex. Genes Dev. 18, 1649–
1654.
Yoon, J.C., Puigserver, P., Chen, G., Donovan, J., Wu, Z., Rhee, J., Adelmant,
G., Stafford, J., Kahn, C.R., Granner, D.K., et al. (2001). Control of hepatic
gluconeogenesis through the transcriptional coactivator PGC-1. Nature 413,
131–138.
